Targeted alpha therapy for metastatic breast cancer using alpha-Herceptin

这项提议的具体目的是在非人类灵长类动物身上展示一种专利的新平台疫苗技术(杂乱抗原疫苗或Savine)的概念验证，该技术旨在编码感染性病原体的所有蛋白质序列，在这种情况下是HIV-1。它们被排列成大小相等的重叠片段，从而保持诱导广泛的T细胞介导的免疫所需的所有潜在的T细胞表位。这种人工设计的疫苗使用HIV-1的共同序列，为全球人口提供对主要HIV-1毒株的普遍覆盖。合成的系统设计的HIV-1疫苗将使用我们新开发的主要增强免疫制度来提供，该制度可诱导特别高水平的细胞介导免疫。

The specific aim of this proposal is to demonstrate, in non-human primates, proof–of-concept of a patented new platform vaccine technology (scrambled antigen vaccine or SAVINE) designed to encode all the protein sequences of an infectious agent, in this case HIV-1. These are arranged as equal-sized, overlapping fragments such that all potential T cell epitopes that are needed to induce broad T-cell-mediated immunity are maintained. The synthetically designed vaccine uses consensus sequences of HIV-1 to provide universal coverage of the major HIV-1 strains for a global population. The synthetic systematically designed HIV-1 vaccine will be delivered using our newly developed prime-boost immunisation regime that induces particularly high levels of cell-mediated immunity.